{
  "state": "mississippi",
  "path": "title-title-41-public-health-41-1-1-41-149-11/chapter-chapter-149-defending-affordable-prescription-drug-costs-act",
  "sections": [
    {
      "id": "section-41-149-1",
      "number": "41-149-1",
      "heading": "Short titleSection 41-149-3 - DefinitionsSection 41-149-5 - Prohibition of certain discriminatory actions related to reimbursement of 340B entitiesSection 41-149-7 - Prohibition of certain discriminatory actions by a manufacturer or distributor related to 340B entitiesSection 41-149-9 - ViolationsSe",
      "text": "This act may be cited as the \"Defending Affordable Prescription Drug Costs Act\".Added by Laws, 2024, ch. 319, HB 728,§ 1, eff. 7/1/2024.\n\nThis act may be cited as the \"Defending Affordable Prescription Drug Costs Act\".Added by Laws, 2024, ch. 319, HB 728,§ 1, eff. 7/1/2024.\n\nThis act may be cited as the \"Defending Affordable Prescription Drug Costs Act\".Added by Laws, 2024, ch. 319, HB 728,§ 1, eff. 7/1/2024.\n\nThis act may be cited as the \"Defending Affordable Prescription Drug Costs Act\".\n\nAdded by Laws, 2024, ch. 319, HB 728,§ 1, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-149/section-41-149-1/"
    },
    {
      "id": "section-41-149-3",
      "number": "41-149-3",
      "heading": "Definitions",
      "text": "As used in this act, the following terms have the following meanings:(a)\"340B drug\" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to42 USC 256band is purchased by a covered entity as defined in42 USC 256b(a)(4).(b)\"340B entity\" means an entity participating or authorized to participate in the federal 340B drug discount program, as described in42 USC 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B drug discount program.(c)\"Health insurance issuer\" means an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the Commissioner of Insurance, that contracts or offers to contract, or enters into an agreement to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services, including an accident and sickness insurance company, a health maintenance organization, a preferred provider organization or any similar entity, or any other entity providing a health insurance plan as defined in Section73-21-153.(d)\"Manufacturer\" has the same meaning as defined in Section73-21-73.(e)\"Pharmacy\" has the same meaning as defined in Section73-21-73.(f)\"Pharmacy benefit manager\" has the same meaning as defined in Section73-21-153.Added by Laws, 2024, ch. 319, HB 728,§ 2, eff. 7/1/2024.\n\nAs used in this act, the following terms have the following meanings:(a)\"340B drug\" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to42 USC 256band is purchased by a covered entity as defined in42 USC 256b(a)(4).(b)\"340B entity\" means an entity participating or authorized to participate in the federal 340B drug discount program, as described in42 USC 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B drug discount program.(c)\"Health insurance issuer\" means an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the Commissioner of Insurance, that contracts or offers to contract, or enters into an agreement to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services, including an accident and sickness insurance company, a health maintenance organization, a preferred provider organization or any similar entity, or any other entity providing a health insurance plan as defined in Section73-21-153.(d)\"Manufacturer\" has the same meaning as defined in Section73-21-73.(e)\"Pharmacy\" has the same meaning as defined in Section73-21-73.(f)\"Pharmacy benefit manager\" has the same meaning as defined in Section73-21-153.Added by Laws, 2024, ch. 319, HB 728,§ 2, eff. 7/1/2024.\n\nAs used in this act, the following terms have the following meanings:(a)\"340B drug\" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to42 USC 256band is purchased by a covered entity as defined in42 USC 256b(a)(4).(b)\"340B entity\" means an entity participating or authorized to participate in the federal 340B drug discount program, as described in42 USC 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B drug discount program.(c)\"Health insurance issuer\" means an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the Commissioner of Insurance, that contracts or offers to contract, or enters into an agreement to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services, including an accident and sickness insurance company, a health maintenance organization, a preferred provider organization or any similar entity, or any other entity providing a health insurance plan as defined in Section73-21-153.(d)\"Manufacturer\" has the same meaning as defined in Section73-21-73.(e)\"Pharmacy\" has the same meaning as defined in Section73-21-73.(f)\"Pharmacy benefit manager\" has the same meaning as defined in Section73-21-153.Added by Laws, 2024, ch. 319, HB 728,§ 2, eff. 7/1/2024.\n\nAs used in this act, the following terms have the following meanings:\n\nAdded by Laws, 2024, ch. 319, HB 728,§ 2, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-149/section-41-149-3/"
    },
    {
      "id": "section-41-149-5",
      "number": "41-149-5",
      "heading": "Prohibition of certain discriminatory actions related to reimbursement of 340B entities",
      "text": "(1)(a)With respect to reimbursement to a 340B entity for 340B drugs, a health insurance issuer, pharmacy benefit manager, other third-party payor, or its agent shall not do any of the following:(i)Reimburse a 340B entity for 340B drugs at a rate lower than that paid for the same drug to entities that are not 340B entities or lower reimbursement for a claim on the basis that the claim is for a 340B drug.(ii)Impose any terms or conditions on any 340B entity with respect to any of the following that differ from such terms or conditions applied to non-340B entities on the basis that the entity participates in the federal 340B drug discount program set forth in42 USC 256bor that a drug is a 340B drug including, without limitation, any of the following:1.Fees, charges, clawbacks, or other adjustments or assessments. For purposes of this item 1, the term \"other adjustment\" includes placing any additional requirements, restrictions, or unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B entity that are not placed upon other entities that do not participate in the 340B drug discount program, including affiliate pharmacies of the health insurance issuer, pharmacy benefit manager, or other third-party payor.2.Dispensing fees that are less than the dispensing fees for non-340B entities.3.Restrictions or requirements regarding participation in standard or preferred pharmacy networks.4.Requirements relating to the frequency or scope of audits of inventory management systems.5.Requirements that a claim for a drug include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Division of Medicaid for the administration of the Mississippi Medicaid program.6.Any other restrictions, conditions, practices, or policies that are not imposed on non-340B entities.(iii)Require a 340B entity to reverse, resubmit, or clarify a claim after the initial adjudication unless these actions are in the normal course of pharmacy business and not related to 340B drug pricing.(iv)Discriminate against a 340B entity in a manner that prevents or interferes with any patient's choice to receive such drugs from the 340B entity, including the administration of such drugs. For purposes of this subparagraph (iv), it is considered a discriminatory practice that prevents or interferes with a patient's choice to receive drugs at a 340B entity if a health insurance issuer, pharmacy benefit manager, or other third-party payor places any additional requirements, restrictions, or unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B entity, including but not limited to requiring a claim for a drug to include any identification, billing modifier, attestation or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Division of Medicaid in administration of the Mississippi Medicaid program.(v)Include any other provision in a contract between a health insurance issuer, pharmacy benefit manager, or other third-party payor and a 340B entity that discriminates against the 340B entity or prevents or interferes with an individual's choice to receive a prescription drug from a 340B entity, including the administration of the drug, in person or via direct delivery, mail, or other form of shipment, or creation of a restriction or additional charge on a patient who chooses to receive drugs from a 340B entity.(vi)Require or compel the submission of ingredient costs or pricing data pertaining to 340B drugs to any health insurance issuer, pharmacy benefit manager, or other third-party payor.(vii)Exclude any 340B entity from the health insurance issuer, pharmacy benefit manager, or other third-party payor network on the basis that the 340B entity dispenses drugs subject to an agreement under42 USC 256b, or refusing to contract with a 340B entity for reasons other than those that apply equally to non-340B entities.(2)Nothing in this act applies to the Mississippi Medicaid program as payor when Medicaid provides reimbursement for covered outpatient drugs as defined in42 USC 1396r-8(k).Added by Laws, 2024, ch. 319, HB 728,§ 3, eff. 7/1/2024.\n\n(1)(a)With respect to reimbursement to a 340B entity for 340B drugs, a health insurance issuer, pharmacy benefit manager, other third-party payor, or its agent shall not do any of the following:(i)Reimburse a 340B entity for 340B drugs at a rate lower than that paid for the same drug to entities that are not 340B entities or lower reimbursement for a claim on the basis that the claim is for a 340B drug.(ii)Impose any terms or conditions on any 340B entity with respect to any of the following that differ from such terms or conditions applied to non-340B entities on the basis that the entity participates in the federal 340B drug discount program set forth in42 USC 256bor that a drug is a 340B drug including, without limitation, any of the following:1.Fees, charges, clawbacks, or other adjustments or assessments. For purposes of this item 1, the term \"other adjustment\" includes placing any additional requirements, restrictions, or unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B entity that are not placed upon other entities that do not participate in the 340B drug discount program, including affiliate pharmacies of the health insurance issuer, pharmacy benefit manager, or other third-party payor.2.Dispensing fees that are less than the dispensing fees for non-340B entities.3.Restrictions or requirements regarding participation in standard or preferred pharmacy networks.4.Requirements relating to the frequency or scope of audits of inventory management systems.5.Requirements that a claim for a drug include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Division of Medicaid for the administration of the Mississippi Medicaid program.6.Any other restrictions, conditions, practices, or policies that are not imposed on non-340B entities.(iii)Require a 340B entity to reverse, resubmit, or clarify a claim after the initial adjudication unless these actions are in the normal course of pharmacy business and not related to 340B drug pricing.(iv)Discriminate against a 340B entity in a manner that prevents or interferes with any patient's choice to receive such drugs from the 340B entity, including the administration of such drugs. For purposes of this subparagraph (iv), it is considered a discriminatory practice that prevents or interferes with a patient's choice to receive drugs at a 340B entity if a health insurance issuer, pharmacy benefit manager, or other third-party payor places any additional requirements, restrictions, or unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B entity, including but not limited to requiring a claim for a drug to include any identification, billing modifier, attestation or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Division of Medicaid in administration of the Mississippi Medicaid program.(v)Include any other provision in a contract between a health insurance issuer, pharmacy benefit manager, or other third-party payor and a 340B entity that discriminates against the 340B entity or prevents or interferes with an individual's choice to receive a prescription drug from a 340B entity, including the administration of the drug, in person or via direct delivery, mail, or other form of shipment, or creation of a restriction or additional charge on a patient who chooses to receive drugs from a 340B entity.(vi)Require or compel the submission of ingredient costs or pricing data pertaining to 340B drugs to any health insurance issuer, pharmacy benefit manager, or other third-party payor.(vii)Exclude any 340B entity from the health insurance issuer, pharmacy benefit manager, or other third-party payor network on the basis that the 340B entity dispenses drugs subject to an agreement under42 USC 256b, or refusing to contract with a 340B entity for reasons other than those that apply equally to non-340B entities.(2)Nothing in this act applies to the Mississippi Medicaid program as payor when Medicaid provides reimbursement for covered outpatient drugs as defined in42 USC 1396r-8(k).Added by Laws, 2024, ch. 319, HB 728,§ 3, eff. 7/1/2024.\n\n(1)(a)With respect to reimbursement to a 340B entity for 340B drugs, a health insurance issuer, pharmacy benefit manager, other third-party payor, or its agent shall not do any of the following:(i)Reimburse a 340B entity for 340B drugs at a rate lower than that paid for the same drug to entities that are not 340B entities or lower reimbursement for a claim on the basis that the claim is for a 340B drug.(ii)Impose any terms or conditions on any 340B entity with respect to any of the following that differ from such terms or conditions applied to non-340B entities on the basis that the entity participates in the federal 340B drug discount program set forth in42 USC 256bor that a drug is a 340B drug including, without limitation, any of the following:1.Fees, charges, clawbacks, or other adjustments or assessments. For purposes of this item 1, the term \"other adjustment\" includes placing any additional requirements, restrictions, or unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B entity that are not placed upon other entities that do not participate in the 340B drug discount program, including affiliate pharmacies of the health insurance issuer, pharmacy benefit manager, or other third-party payor.2.Dispensing fees that are less than the dispensing fees for non-340B entities.3.Restrictions or requirements regarding participation in standard or preferred pharmacy networks.4.Requirements relating to the frequency or scope of audits of inventory management systems.5.Requirements that a claim for a drug include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Division of Medicaid for the administration of the Mississippi Medicaid program.6.Any other restrictions, conditions, practices, or policies that are not imposed on non-340B entities.(iii)Require a 340B entity to reverse, resubmit, or clarify a claim after the initial adjudication unless these actions are in the normal course of pharmacy business and not related to 340B drug pricing.(iv)Discriminate against a 340B entity in a manner that prevents or interferes with any patient's choice to receive such drugs from the 340B entity, including the administration of such drugs. For purposes of this subparagraph (iv), it is considered a discriminatory practice that prevents or interferes with a patient's choice to receive drugs at a 340B entity if a health insurance issuer, pharmacy benefit manager, or other third-party payor places any additional requirements, restrictions, or unnecessary burdens upon the 340B entity that results in administrative costs or fees to the 340B entity, including but not limited to requiring a claim for a drug to include any identification, billing modifier, attestation or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Division of Medicaid in administration of the Mississippi Medicaid program.(v)Include any other provision in a contract between a health insurance issuer, pharmacy benefit manager, or other third-party payor and a 340B entity that discriminates against the 340B entity or prevents or interferes with an individual's choice to receive a prescription drug from a 340B entity, including the administration of the drug, in person or via direct delivery, mail, or other form of shipment, or creation of a restriction or additional charge on a patient who chooses to receive drugs from a 340B entity.(vi)Require or compel the submission of ingredient costs or pricing data pertaining to 340B drugs to any health insurance issuer, pharmacy benefit manager, or other third-party payor.(vii)Exclude any 340B entity from the health insurance issuer, pharmacy benefit manager, or other third-party payor network on the basis that the 340B entity dispenses drugs subject to an agreement under42 USC 256b, or refusing to contract with a 340B entity for reasons other than those that apply equally to non-340B entities.(2)Nothing in this act applies to the Mississippi Medicaid program as payor when Medicaid provides reimbursement for covered outpatient drugs as defined in42 USC 1396r-8(k).Added by Laws, 2024, ch. 319, HB 728,§ 3, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 319, HB 728,§ 3, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-149/section-41-149-5/"
    },
    {
      "id": "section-41-149-7",
      "number": "41-149-7",
      "heading": "Prohibition of certain discriminatory actions by a manufacturer or distributor related to 340B entities",
      "text": "(1)A manufacturer or distributor shall not deny, restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity unless such receipt is prohibited by the United States Department of Health and Human Services.(2)A manufacturer or distributor shall not interfere with a pharmacy contracted with a 340B entity.Added by Laws, 2024, ch. 319, HB 728,§ 4, eff. 7/1/2024.\n\n(1)A manufacturer or distributor shall not deny, restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity unless such receipt is prohibited by the United States Department of Health and Human Services.(2)A manufacturer or distributor shall not interfere with a pharmacy contracted with a 340B entity.Added by Laws, 2024, ch. 319, HB 728,§ 4, eff. 7/1/2024.\n\n(1)A manufacturer or distributor shall not deny, restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity unless such receipt is prohibited by the United States Department of Health and Human Services.(2)A manufacturer or distributor shall not interfere with a pharmacy contracted with a 340B entity.Added by Laws, 2024, ch. 319, HB 728,§ 4, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 319, HB 728,§ 4, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-149/section-41-149-7/"
    },
    {
      "id": "section-41-149-9",
      "number": "41-149-9",
      "heading": "Violations",
      "text": "The commission of any act prohibited by this act is considered a violation of the Consumer Protection Act, Sections75-24-1through75-24-29, and subjects the violator to any and all actions, including investigative demands, remedies, and penalties provided for in those sections, except there shall be no right to bring a private action. A violation occurs each time a prohibited act is committed.Added by Laws, 2024, ch. 319, HB 728,§ 5, eff. 7/1/2024.\n\nThe commission of any act prohibited by this act is considered a violation of the Consumer Protection Act, Sections75-24-1through75-24-29, and subjects the violator to any and all actions, including investigative demands, remedies, and penalties provided for in those sections, except there shall be no right to bring a private action. A violation occurs each time a prohibited act is committed.Added by Laws, 2024, ch. 319, HB 728,§ 5, eff. 7/1/2024.\n\nThe commission of any act prohibited by this act is considered a violation of the Consumer Protection Act, Sections75-24-1through75-24-29, and subjects the violator to any and all actions, including investigative demands, remedies, and penalties provided for in those sections, except there shall be no right to bring a private action. A violation occurs each time a prohibited act is committed.Added by Laws, 2024, ch. 319, HB 728,§ 5, eff. 7/1/2024.\n\nThe commission of any act prohibited by this act is considered a violation of the Consumer Protection Act, Sections75-24-1through75-24-29, and subjects the violator to any and all actions, including investigative demands, remedies, and penalties provided for in those sections, except there shall be no right to bring a private action. A violation occurs each time a prohibited act is committed.\n\nAdded by Laws, 2024, ch. 319, HB 728,§ 5, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-149/section-41-149-9/"
    },
    {
      "id": "section-41-149-11",
      "number": "41-149-11",
      "heading": "Federal preemption",
      "text": "(1)Nothing in this act is to be construed or applied to be less restrictive than federal law for a person or entity regulated by this act.(2)Nothing in this act is to be construed or applied to be in conflict with any of the following:(a)Applicable federal law and related regulations.(b)Other laws of this state if the state law is compatible with applicable federal law.(3)Limited distribution of a drug required under21 USC 355-1is not to be construed as a violation of this act.Added by Laws, 2024, ch. 319, HB 728,§ 6, eff. 7/1/2024.\n\n(1)Nothing in this act is to be construed or applied to be less restrictive than federal law for a person or entity regulated by this act.(2)Nothing in this act is to be construed or applied to be in conflict with any of the following:(a)Applicable federal law and related regulations.(b)Other laws of this state if the state law is compatible with applicable federal law.(3)Limited distribution of a drug required under21 USC 355-1is not to be construed as a violation of this act.Added by Laws, 2024, ch. 319, HB 728,§ 6, eff. 7/1/2024.\n\n(1)Nothing in this act is to be construed or applied to be less restrictive than federal law for a person or entity regulated by this act.(2)Nothing in this act is to be construed or applied to be in conflict with any of the following:(a)Applicable federal law and related regulations.(b)Other laws of this state if the state law is compatible with applicable federal law.(3)Limited distribution of a drug required under21 USC 355-1is not to be construed as a violation of this act.Added by Laws, 2024, ch. 319, HB 728,§ 6, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 319, HB 728,§ 6, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-149/section-41-149-11/"
    }
  ]
}